SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 24, 2020
(Exact Name of Registrant as Specified in its Charter)
|(State or Other Jurisdiction of Incorporation)||(Commission File Number)||(I.R.S. Employer Identification Number)|
1350 Old Bayshore Highway,
Burlingame, California 94010
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock, par value $0.01 per share||INVA||The NASDAQ Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|Item 5.07.||Submission of Matters to a Vote of Security Holders.|
At the Annual Meeting of Stockholders held on April 24, 2020 (the “Meeting”), our stockholders elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockholders in 2021, as follows:
|George W. Bickerstaff, III||56,694,320||32,618,767||4,720,442|
|Mark DiPaolo, Esq.||56,166,516||33,146,571||4,720,442|
|Odysseas D. Kostas, M.D.||56,304,404||33,008,683||4,720,442|
|Sarah Schlesinger, M.D.||55,808,366||33,504,721||4,720,442|
At the Meeting, our stockholders next approved on a non-binding advisory basis, Innoviva’s 2019 executive compensation. The vote for such approval was 54,326,646 shares for, 34,922,378 shares against, 64,063 shares abstaining, and 4,720,442 shares of broker non-votes.
Also at the Meeting, our stockholders ratified the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020. The vote for such ratification was 93,803,143 shares for, 187,350 shares against, 43,036 shares abstaining and no broker non-votes.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: April 28, 2020||By:||/s/ Geoffrey Hulme|
|Interim Principal Executive Officer|